10x Genomics announced three clinically focused collaborations and plans to open a CLIA‑certified lab in early 2027 to move single‑cell and spatial assays into regulated clinical workflows. Partnerships with Dana‑Farber, the Cancer Research Institute and Brigham and Women’s Hospital will generate large oncology and immunology datasets—hundreds to thousands of samples—to benchmark biomarkers of response, resistance and immune signatures. The company said it will use Chromium single‑cell and Xenium spatial platforms to build datasets for AI benchmarking and translational assay development. 10x’s move formalizes a longer‑standing industry shift: single‑cell and spatial technologies transitioning from discovery tools to clinical decision support, and it raises questions about assay standardization, CLIA lab operations, and reimbursement for multiomic diagnostics.